

February 17, 2021



Artelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

Research demonstrates co-administration of CBD and TMP could confer ART12.11 with a more desirable pharmacodynamic profile

LA JOLLA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- [Artelo Biosciences, Inc.](#) (**NASDAQ: ARTL**) today announced that Saoirse O'Sullivan, Ph.D., Professor of Pharmacology and Scientific Advisor to Artelo, along with Ryan Maguire and Dr. Timothy England of the University of Nottingham, have generated data showing potential pharmacodynamic interactions of co-administration of cannabidiol (CBD) and tetramethylpyrazine (TMP) in cell-based models of cancer. The research focused on the components of Artelo's proprietary CBD:TMP cocrystal program, also known as ART12.11.

Professor O'Sullivan noted, "CBD and TMP are both molecules of therapeutic interest, but whose utility is limited by their poor bioavailability. Through this research, we sought to determine whether a CBD-TMP co-administration could confer additive or synergistic biological actions through pharmacodynamic interactions. Since both molecules are potential anti-cancer agents, we investigated whether there would be an interaction at a cellular level between these molecules in human cancer cell lines. We found that there were synergistic and additive interactions between CBD and TMP in their abilities to prevent cancer cell growth and to kill cancer cells. However, there was also a small reduction in the anti-migratory effect of CBD when TMP was present. We believe these positive initial studies warrant further *in vivo* preclinical research in animal tumor models, where we also expect to see a pharmacokinetic interaction leading to improved drug exposure with the CBD:TMP cocrystal compared to either molecular alone."

"We are highly encouraged by the results of this preclinical research and look forward to reporting the full results at a future scientific conference," noted Gregory Gorgas, Artelo's President & Chief Executive Officer. "The study observed enhanced effects between CBD and TMP, versus either compound alone, reinforcing our confidence in the potential for enhanced efficacy of our proprietary CBD cocrystal. Moreover, the fact we have been awarded a composition of matter patent provides us with the prospect of strong market exclusivity, thereby allowing us to pursue clinical approval and commercialization for a wide range of indications."

About Artelo Biosciences

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a

portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: [@ArteloBio](https://twitter.com/ArteloBio).

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com



Source: Artelo Biosciences